Menu
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, The company advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
300 Boston Scientific Way
Marlborough, Massachusetts 01752-1291
Phone: 15086834000
www.bostonscientific.com
No summary available.
Today we will be looking at hypergrowth stocks with the potential to 10X your investment. All but one of the stocks discussed below has achieved hypergrowth – growing by 40% or more – over the last 12 months. Each share is also priced at less than $100 with most shares well below $100. I have chosen that price level because 10X growth is difficult if the share is priced above $100. None of the stocks discussed below trade for less than $10. Instead, these companies tend to be relatively well established and growing rapidly. That means for the most part they represent relatively stable investments overall with high upside potential. Most of the companies discussed here are also relatively stable from the perspective of earnings. These companies have achieved net profitability and our forecast to continue doing so. In essence, they are essentially middle market firms with strong fundamentals and strong upside. They aren’t the biggest names but those who choose to invest very well may be rewarded handsomely.
An update from Boston Scientific (BSX) is now available. Boston Scientific Corporation has expanded its Board from ten to eleven members, appointin…
2024 has been a great year for U.S. indices, with the benchmark S&P 500 posting new all-time highs 38 times so far. The rally has been primarily driven by the tech sector , focusing on artificial intelligence (AI). Several record-breaking stocks have seen triple-digit returns. However, the markets appear to have taken a summer breather in July. This raises the question of whether it’s time to buy the dip under the theory that record-breaking stocks have more upside ahead . While AI stocks have been the leader in terms of gains, it is not the only play. Analysts have worried that the market has become top-heavy, with a relatively small number of companies concentrating many of the gains. Yet, given the focus on tech, the Nasdaq could be the better-performing index this year. Stocks that have already risen significantly do not necessarily become overvalued. If their income has managed to keep up or surpass the share price, then they can still maintain their valuations. Here are three record-breaking stocks that might have more upside ahead in this environment: Dell Technologies (DELL) Source: Ken Wolter / Shutterstock.com The company best known for its personal computers has developed various IT solutions.
Sellers continued in the US stocks at the start of the day, especially in the Nasdaq and S&P indices. Each of them continued what was started yesterday when both had their worst trading day since the end of 2022. For the S&P it fell -36.17 points before bottoming. For the Nasdaq it tumbled -308.45 points a day after falling -655 points. That''s like close to -1000 points. Then things turned around with the S&P moving to +64 points at the high for the day. The Nasdaq moved to up 202.05 points at session highs (a 500+ point turnaround).. However, the gains were not meant to be and both are closing the day down on the day. The Dow and the small-cap Russell 2000 indices bounced higher as the flow of funds come out of tech and into the underperforming sector.. The final numbers for the indices are showing: Dow Industrial Average average plus 81.20 points or 0.20 percent at 39935.08 S&P index fell -27.89 points or -0.81% at 5399.23 NASDAQ index tumbled -160.69 points or -0.93% at 17181.72 The small-cap Russell 2000 rose 27.60 points or 1.26% at 2222.98.
Boston Scientific Corporation (NYSE: BSX ) generated second-quarter revenues of $4.12 billion, beating the consensus estimate of $4.02 billion . Sales increased 14.5% on a reported basis, compared to the company’s guidance range of 10.5%-12.5% and 16.1% on an operational basis, 14.7% on an organic basis, compared to the company’s guidance range of 10%-12% . The company earned an adjusted EPS of $0.62, beating the consensus of $0.58 and the management guidance of … Full story available on Benzinga.com
Boston Scientific''s second-quarter earnings and revenue got a boost from high demand for its heart devices.
Boston Scientific Corporation (NYSE:NYSE:BSX) Q2 2024 Earnings Conference Call July 24, 2024 8:00 AM ETCompany ParticipantsJon Monson - SVP, IRMichael F.
